ProMIS reports Q3 2026 and announces PRECISE-AD data timing
ProMIS Neurosciences reported financial results for Q3 2026 and anticipates topline data from its early-stage Alzheimer's antibody trial later in 2027; Chief Commercial Officer Ivana Rubino was named to the leadership team.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed